Acute kidney tubular necrosis

Summary

Acute kidney tubular necrosis (MONDO:0006637) is a disease and 4 clinical trials. Top therapeutic interventions include sodium chloride. A subtype of acute kidney injury — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	acute kidney tubular necrosis
Mondo ID	MONDO:0006637
EFO	EFO:1000794
MeSH	D007683
DOID	DOID:12556
ICD-10-CM	N17.0
NCIT	C34749
SNOMED CT	35455006
UMLS	C0022672
MedGen	7213
MedDRA	10023441
Is cancer (heuristic)	no

Also known as: acute renal failure with lesion of tubular necrosis · acute renal failure with tubular necrosis · acute tubular necrosis

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of acute kidney injury. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › kidney disorder › kidney failure › acute kidney injury › acute kidney tubular necrosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1/PHASE2	2
PHASE2/PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07161843	PHASE2/PHASE3	NOT_YET_RECRUITING	Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)
NCT02561767	PHASE1/PHASE2	UNKNOWN	Effect of BM-MSCs in DCD Kidney Transplantation
NCT02563366	PHASE1/PHASE2	UNKNOWN	Effect of BM-MSCs on Early Graft Function Recovery After DCD Kidney Transplant.
NCT02889575	Not specified	COMPLETED	Predictive Value of PIIINP and Urinary NGAL in Renal Function Recovery

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
SODIUM CHLORIDE	4	2